RT Journal Article
T1 The systemic impact of non-surgical treatment of peri-implantitis with or without adjunctive systemic metronidazole: Secondary analysis of a randomized clinical trial
A1 Liñares, Antonio
A1 Dopico, Jose
A1 Blanco, Carlota
A1 Pico, Alex
A1 Sobrino, Tomás
A1 Blanco Carrión, Juan
A1 Leira Feijóo, Yago
K1 Antibiotic
K1 Caridovascular disease
K1 C-reactive protein
K1 Infammation
K1 Peri-implantitis
K1 Treatment
AB ObjectivesThe aim of this study was to evaluate the systemic effect of non-surgical peri-implantitis treatment (NSPIT) with or without the administration of systemic metronidazole.MethodsIn this secondary analysis from a previously published clinical trial (NCT03564301), peri-implantitis patients were randomized into two groups: test, receiving NSPIT plus 500 mg of oral systemic metronidazole three times a day for 7 days (n = 10); and control group, receiving NSPIT plus placebo (n = 11). Serum samples were obtained at baseline, 3 and 6 months after therapy to determine levels of inflammatory biomarkers, lipid fractions and complete blood counts.ResultsBoth treatment modalities produced improvements in clinical and radiographic parameters. After 6 months from NSPIT, a substantial reduction in C-reactive protein (6.9 mg/dL; 95% CI: 3.7 to 9.9, p < .001) and low-density lipoprotein cholesterol (21.8 mg/dL; 95% CI: −6.9 to 50.5, p = .013) as well as a modest increase in neutrophils counts (0.4 × 103/μL; 95% CI: −0.4 to 1.1, p = .010) was observed in the control group while the test group showed a significant reduction of TNF-α (110.1; 95% CI: 38.9 to 181.4, p = .004).ConclusionsNSPIT showed a short-term beneficial systemic effect regardless of adjunctive use of systemic metronidazole.
PB Wiley
SN 0905-7161
YR 2024
FD 2024-08-02
LK https://hdl.handle.net/10347/39744
UL https://hdl.handle.net/10347/39744
LA eng
NO Liñares, A., Dopico, J., Blanco, C., Pico, A., Sobrino, T., Blanco, J., & Leira, Y. (2024). The systemic impact of non-surgical treatment of peri-implantitis with or without adjunctive systemic metronidazole: Secondary analysis of a randomized clinical trial. Clinical Oral Implants Research, 35, 1519–1530.
NO This study was partially supported by grants from the Osteology Foundation (APB-MET-16-070) and CIBERNED – Institute of Health Carlos III – European Regional Development Fund (CB22_05_00067). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
DS Minerva
RD 28 abr 2026